ETIHX - Eventide Healthcare & Life Sciences I

Nasdaq - Nasdaq Delayed Price. Currency in USD
-0.67 (-2.11%)
As of 8:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close31.78
YTD Return9.40%
Expense Ratio (net)1.34%
Morningstar Rating★★★☆☆
Morningstar Risk RatingHigh
Last Cap Gain0.00
Net Assets544.59M
Beta (3y)1.61
Holdings Turnover27.00%
Last Dividend0.00
Inception DateDec 27, 2012
Average for CategoryN/A
  • PR Newswire2 months ago

    Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings for 2017

    BOSTON, Jan. 30, 2018 /PRNewswire/ -- The Eventide Gilead Fund (ETILX) and the Eventide Healthcare & Life Sciences Fund (ETIHX) were both named as "Category Kings" by the Wall Street Journal for 2017. Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser that designs investments for performance and a better world. Eventide CEO Robin John commented, "We are pleased with the results, yet more importantly, proud of how they were achieved.

  • PR Newswire2 months ago

    Eventide Healthcare & Life Sciences Fund Ranks Top 1% in Health Funds for the 5yr Period

    BOSTON, Jan. 29, 2018 /PRNewswire/ -- The Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX *), which celebrated its five-year anniversary in December, completed the five-year period ending December 31, 2017 in the top 1% of the Morningstar Health category for total return out of 121 funds. The Wall Street Journal also named the Fund a "Category King" for 2017 for ranking in the top 10 Health & Biotech funds based on total return (ranking #3 out of 99 funds).

  • We're sorry this is all we were able to find about this topic.